The pharmacological treatment of depression in adults with epilepsy

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 18, 2008, Pages 3159-3168

  Mula, Marco ^a   Schmitz, Bettina ^b   Sander, Josemir W ^c,d  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

antidepressant drugs; antiepileptic drugs; depression; epilepsy; seizures

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT;

ADULT; DEPRESSION; DRUG INTERACTION; EPILEPSY; HUMAN; PROGNOSIS; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG INTERACTIONS; EPILEPSY; HUMANS; PROGNOSIS; TREATMENT OUTCOME;

EID: 59449100938     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656560802587024     Document Type: Review

References (82)

1. Kanner AM. Depression in epilepsy: a frequently neglected multifaceted disorder. Epilepsy Behav 2003;4:S11-19
2. Gaitatzis A, Trimble MR, Sander JW The psychiatric comorbidity of epilepsy Acta Neurol Scand 2004;110:207-20
3. Marcangelo MJ, Ovsiew F. Psychiatric aspects of epilepsy Psychiatr Clin North Am 2007;30:781-802
4. Seethalakshmi R, Krishnamoorthy ES. Depression in epilepsy: phenomenology diagnosis and management. Epileptic Disord 2007;9:1-10
5. Perrine K, Hermann BP, Meador KJ, et al. The relationship of neuropsychological functioning to quality of life in epilepsy Arch Neurol 1995;52:997-1003
6. Gilliam F, Kuzniecky R, Faught E, et al. Patient Validated Content of Epilepsy Specific Quality of Life Measurement. Epilepsia 1997;38:233-6
7. Gilliam F. The impact of epilepsy on subjective health status. Curr Neurol Neurosci Rep 2003;3:357-62
8. Boylan LS, Flint LA, Labovitz DL, et al. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy Neurology 2004;62:258-61
9. Harden CL, Maroof DA, Nikolov B, et al. The effect of seizure severity on quality of life in epilepsy. Epilepsy Behav 2007;11:208-11
10. Turky A, Beavis JM, Thapar AK, et al. Psychopathology in children and adolescents with epilepsy: an investigation of predictive variables. Epilepsy Behav 2008;12:136-44
11. Lambert MV, Robertson MM. Depression in epilepsy: etiology phenomenology, and treatment. Epilepsia 1999;40(Suppl 10):S21-47
12. Edeh J, Toone B. Relationship between interictal psychopathology and type of epilepsy. Results of a survey in general practice. Br J Psychiatry 1987;151:95-101
13. Tellez-Zenteno JF, Patten SB, Jetté N, et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007;48:2336-44
14. Ettinger A, Reed M, Cramer J. Epilepsy Impact Project Group. Depression and comorbidity in community-based patients with epilepsy or asthma. Neurology 2004;63:1008-14
15. Jacoby A, Baker GA, Steen N, et al. The clinical course of epilepsy and its psychosocial correlates: findings from a UK Community Study. Epilepsia 1996;37:148-61
16. O'Donoghue MF, Goodridge DM, Redhead K, et al. Assessing the psychosocial consequences of epilepsy: a community-based study. Br J Gen Pract 1999;49:211-4
17. Ring HA, Moriarty J, Trimble MR. A perspective study of the early post surgical psychiatric associations of epilepsy surgery. J Neurol Neurosurg Psychiatry 1998;64:601-4
18. Victoroff JI, Benson F, Grafton ST, et al. Depression in complex partial seizures. Electroencephalography and cerebral metabolic correlates. Arch. Neurol 1994;51:155-63
19. Mendez MF, Cummings JL, Benson DF, et al. Depression in epilepsy: significance and phenomenology. Arch Neurol 1986;43:766-70
20. Kanner AM, Kozac AM, Frey M. The use of sertraline in patients with epilepsy: is it safe? Epilepsy Behav 2000;1:100-5
21. Mula M, Jauch R, Cavanna A, et al. Clinical and psychopathological definition of the interictal dysphoric disorder of epilepsy. Epilepsia 2008;49:650-656
22. Jones JE, Hermann BP, Barry JJ, et al. Clinical assessment of Axis I psychiatric morbidity in chronic epilepsy: a multicenter investigation. J Neuropsychiatry Clin Neurosci 2005;17:172-9
23. Blumer D, Montouris G, Davies K. The interictal dysphoric disorder: recognition, pathogenesis, and treatment of the major psychiatric disorder of epilepsy. Epilepsy Behav 2004;5:826-40
24. Kraepelin E. Psychiatrie. Band 3. Leipzig: Johann Ambrosius Barth, 1923 Bleuler E. Lehrbuch der Psychiatrie. 8th edition. Berlin: Springer-Verlag, 1949
25. Gastaut H, Morin G, Lesevre N. Etude du comportement des epileptiques psychomoteurs dans l'intervalle de leurs crises: les troubles de l'activitè globale et de la sociabilitè. Ann Med Psychol Paris.1955;113:1-27
26. Kanner AM, Soto A, Gross-Kanner H. Prevalence and clinical characteristics of postictal psychiatric symptoms in partial epilepsy. Neurology 2004;62:708-713
27. Stahl SM. Stahl's Essential Psychopharmacology. 3rd edition. Cambridge: Cambridge University Press, 2008
28. Mula M, Trimble MR. Pharmacokinetic interactions between antiepileptic and antidepressant drugs. World J Biol Psychiatry 2003;4:21-4
29. Ketter TA, Post RM, Parekh PI, et al. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. J Clin Psychiatry 1995;56:471-5
30. Monaco F, Cicolin A. Interaction between anticonvulsant and psychoactive drugs. Epilepsia 1999;40(Suppl 10):S71-6
31. Szymura-Oleksiak J, Wyska E, Wasieczko A. Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. Psychopharmacology Berl.2001;154:38-42
32. Wong SL, Cavanaugh J, Shi H, et al. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther 1996;60:48-53
33. Fehr C, Grunder G, Hiemke C, et al. Increase in serum clomipramine concentrations caused by valproate. J Clin Psychopharmacol 2000;20:493-4
34. Spina E, Avenoso A, Pollicino AM, et al. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993;15:247-50
35. Grimsley SR, Jann MW, Carter JG, et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991;50:10-5
36. Nelson MH, Birnbaum AK, Remmel RP. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. Epilepsy Res 2001;44:71-82
37. Andersen BB, Mikkelsen M, Vesterager A, et al. No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res 1991;10:201-4
38. Leinonen E, Lepola U, Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry 1996;29:156-8
39. Mamiya K, Kojima K, Yukawa E, et al. Phenytoin intoxication induced by fluvoxamine. Ther Drug Monit 2001;23:75-7
40. Haselberger MB, Freedman LS, Tolbert S. Elevated serum phenytoin concentrations associated with coadministration of sertraline. J Clin Psychopharmacol 1997;17:107-9
41. Rapeport WG, Muirhead DC, Williams SA, et al. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J. Clin Psychiatry 1996;57(Suppl 1):24-8
42. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998;7:163-5
43. Rapeport WG, Williams SA, Muirhead DC, et al. Absence of sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 1996;57(Suppl 1):20-3
44. Bonate PL, Kroboth PD, Smith RB, et al. Clonazepam and sertraline: absence of drug interaction in a multiple-dose study. J Clin Psychopharmacol 2000;20:19-27
45. Toy SM, Lucki I, Peirgies AA, et al. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J Clin Pharmacol 1995;35:410-9
46. Nawishy S, Hathaway N, Turner P. Interactions of anticonvulsant drugs with mianserin and nomifensine. Lancet 1981;2:871-2
47. Laroudie C, Salazar DE, Cosson JP, et al. Carbamazepine-nefazodone interaction in healthy subjects. J Clin Psychopharmacol 2000;20:46-53
48. Roth L, Bertschy G. Nefazodone may inhibit the metabolism of carbamazepine: three case reports. Eur Psychiatry 2001;16:320-1
49. Popli AP, Tanquary J, Lamparella V, Masand PS. Bupropion and anticonvulsant drug interactions. Ann Clin Psychiatry 1995;7:99-101
50. Tekle A, al-Kamis KI. Phenytoin-bupropion interaction: effect on plasma phenytoin concentration in the rat. J Pharm Pharmacol 1990;42:799-801
51. Odishaw J, Chen C. Effects of steady state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy 2000;20:1448-53
52. Jobe PC, Browning RS. The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy. Behav 2005;7:602-19
53. Dailey JW, Naritoku DK. Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Biochem Pharmacol 1996;52:1323-9
54. Yan QS, Jobe PC, Dailey JW. Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Eur J Pharmacol 1994;252:105-12
55. Leander JD. Fluoxetine, a selective serotonin-uptake inhibitor, enhances the anticonvulsant effects of phenytoin, carbamazepine and ameltolide (LY201116). Epilepsia 1992;33:573-6
56. Favale E, Rubino V, Mainardi P, et al. Anticonvulsant effect of fluoxetine in humans. Neurology 1995;45:1926-7
57. Albano C, Cupello A, Mainardi P, et al. Successful treatment of epilepsy with serotonin reuptake inhibitors: proposed mechanism. Neurochem Res 2006;31:509-14
58. Torta R, Monaco F. Atypical antipsychotics and serotoninergic antidepressants in patients with epilepsy: pharmacodynamic considerations. Epilepsia 2002;43(Suppl 2):8-13
59. Alper K, Schwartz KA, Koltz RL, et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007;62:345-54
60. Mula M, Schmitz B. Depression in epilepsy-mechanisms and therapeutic approaches. Eur Neurol Dis 2007;2: 58-60
61. Hensiek A, Trimble MR. Relevance of new psychotropic drugs for the neurologist. J Neurol Neurosurg Psychiatry 2002;72:281-5
62. Robertson MM, Trimble MR. The treatment of depression in patients with epilepsy. A double-blind trial. J Affect Disord 1985;9:127-36
63. Blumer D. Dysphoric disorders and paroxysmal affects: recognition and treatment of epilepsy-related psychiatric disorders. Harv Rev Psychiatry 2000;8:8-17
64. Mula M, Monaco F, Trimble MR. Use of psychotropic drugs in patients with epilepsy: interactions and seizure risk. Expert Rev Neurother 2004;4:953-64
65. Kanner AM, Balabanov AJ. Pharmacotherapy of mood disorders in epilepsy: the role of newer psychotropic drugs. Curr Treat Options Neurol 2005;7:281-90
66. Prueter C, Norra C. Mood disorders and their treatment in patients with epilepsy. J Neuropsychiatry Clin Neurosci 2005;17:20-8
67. Thomè-Souza MS, Kuczynski E, Valente KD. Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy Behav 2007;10:417-25
68. Specchio LM, Iudice A, Specchio N, et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol 2004;27:133-6
69. Kuhn KU, Quednow BB, Thiel M, et al. Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy Behav 2003;4:674-9
70. Hovorka J, Herman E, Nemcova II. Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy Behav 2000;1:444-7
71. Wolf P. Manic episodes in epilepsy. In: Akimoto H, Kazamatsuri H, Seino M, Ward AA Jr, editors. Advances in Epileptology: XIIIth Epilepsy International Symposium held in Kyoto Japan. New York: Raven Press, 1982 . p. 237-40
72. Ettinger AB, Reed ML, Goldberg JF, et al. Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology 2005;65:535-540
73. Kramlinger KG, Post RM. Addition of lithium carbonate to carbamazepine: haematological and thyroid effects. Am J Psychiatry 1990;147:615-620
74. Vieweg V, Shutty M, Hundley P, et al. Combined treatment with lithium and carbamazepine. Am J Psychiatry 1991;148:398-399
75. Freeman MP, Stool AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry. 1998; 155: 12-21
76. Chen C, Veronese L, Yin Y. The effects of lamotrigine on the pharmacokinetics of lithium. Br J Clin Pharmacol 2000;50:193-5
77. Abraham G, Owen J. Topiramate can cause lithium toxicity. J Clin Psychopharmacol 2004;24:565-7
78. Erwin CV, Gerber CJ, Morrison SD, et al. Lithium carbonate and convulsive disorders. Arch Gen Psychiatry 1973;28:646-8
79. Jus A, Villenueve A, Gautier J, et al. Influence of lithium carbonate on patients with temporal epilepsy Can Psychiatr Assoc J 1973;18:77-8
80. Barry JJ, Ettinger AB, Friel P, et al. Advisory Group of the Epilepsy Foundation as part of its Mood Disorder. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav 2008;13(Suppl 1):S1-29
81. Trivedi MH, Rush AJ, Wisniewski SR, et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
82. Salpekar JA, Conry JA, Doss W, et al. Clinical experience with anticonvulsant medication in pediatric epilepsy and comorbid bipolar spectrum disorder. Epilepsy Behav 2006;9:327-34.